Cristóbal Belda-Iniesta

7.5k total citations · 1 hit paper
104 papers, 4.8k citations indexed

About

Cristóbal Belda-Iniesta is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Cristóbal Belda-Iniesta has authored 104 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 40 papers in Molecular Biology and 35 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Cristóbal Belda-Iniesta's work include Colorectal Cancer Treatments and Studies (18 papers), Lung Cancer Treatments and Mutations (18 papers) and Glioma Diagnosis and Treatment (13 papers). Cristóbal Belda-Iniesta is often cited by papers focused on Colorectal Cancer Treatments and Studies (18 papers), Lung Cancer Treatments and Mutations (18 papers) and Glioma Diagnosis and Treatment (13 papers). Cristóbal Belda-Iniesta collaborates with scholars based in Spain, United States and United Kingdom. Cristóbal Belda-Iniesta's co-authors include Javier de Castro, Paloma Cejas, Manuel González-Barón, Juan Ángel Fresno Vara, E. Casado, Rosario Perona, Ángel Ayuso‐Sacido, Noemí Garcia‐Romero, Josefa Carrión-Navarro and Enrique Casado and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Cristóbal Belda-Iniesta

103 papers receiving 4.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PI3K/Akt signalling pathway and cancer

2003 1.9k citations E. Casado, Javier de Castro et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cristóbal Belda-Iniesta Spain	30	2.9k	1.4k	1.3k	684	492	104	4.8k
Peng Hou China	41	3.3k 1.1×	1.1k 0.8×	1.3k 0.9×	618 0.9×	546 1.1×	177	5.7k
Alexander T.H. Wu Taiwan	40	2.6k 0.9×	1.1k 0.8×	1.1k 0.8×	684 1.0×	320 0.7×	170	5.1k
Seyed Mahdi Hassanian Iran	41	3.2k 1.1×	1.8k 1.3×	1.4k 1.1×	539 0.8×	484 1.0×	235	5.9k
Ying Yang China	41	2.2k 0.7×	1.3k 0.9×	1.7k 1.2×	868 1.3×	432 0.9×	136	5.1k
Claudio Festuccia Italy	45	2.8k 1.0×	1.1k 0.8×	1.6k 1.2×	1.1k 1.7×	313 0.6×	164	5.3k
Cristiano Ferlini Italy	41	3.0k 1.0×	1.0k 0.7×	1.7k 1.3×	508 0.7×	481 1.0×	136	5.3k
Eugenio Erba Italy	39	2.1k 0.7×	785 0.6×	1.3k 0.9×	609 0.9×	601 1.2×	138	4.6k
Christopher L. Morton United States	45	3.2k 1.1×	663 0.5×	1.5k 1.1×	915 1.3×	406 0.8×	128	5.6k
John P. Fruehauf United States	37	2.1k 0.7×	756 0.5×	1.4k 1.1×	567 0.8×	231 0.5×	100	4.2k
Timothy Madden United States	37	2.1k 0.7×	714 0.5×	1.6k 1.2×	368 0.5×	463 0.9×	108	4.8k

Countries citing papers authored by Cristóbal Belda-Iniesta

Since Specialization

Citations

This map shows the geographic impact of Cristóbal Belda-Iniesta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cristóbal Belda-Iniesta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cristóbal Belda-Iniesta more than expected).

Fields of papers citing papers by Cristóbal Belda-Iniesta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cristóbal Belda-Iniesta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cristóbal Belda-Iniesta. The network helps show where Cristóbal Belda-Iniesta may publish in the future.

Co-authorship network of co-authors of Cristóbal Belda-Iniesta

This figure shows the co-authorship network connecting the top 25 collaborators of Cristóbal Belda-Iniesta. A scholar is included among the top collaborators of Cristóbal Belda-Iniesta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cristóbal Belda-Iniesta. Cristóbal Belda-Iniesta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Carrión-Navarro, Josefa, et al.. (2022). A New Natural Antimycotic Agent is Effective Against Oropharyngeal Candidiasis: The VIPROCAN Study. The Open Dentistry Journal. 16(1). 1 indexed citations

Sánchez-Fresneda, Ruth, José P. Guirao-Abad, Cristóbal Belda-Iniesta, et al.. (2020). Novel Bi-Factorial Strategy against Candida albicans Viability Using Carnosic Acid and Propolis: Synergistic Antifungal Action. Microorganisms. 8(5). 749–749. 12 indexed citations

Medrano, Ignacio Hernández, et al.. (2018). Savana: Re-using Electronic Health Records with Artificial Intelligence. SHILAP Revista de lepidopterología. 1 indexed citations

Ocampo, Sandra M., Vanessa Rodríguez‐Fanjul, Leonor de la Cueva, et al.. (2015). g-force induced giant efficiency of nanoparticles internalization into living cells. Scientific Reports. 5(1). 15160–15160. 8 indexed citations

Sepúlveda-Sánchez, Juan Manuel, Cristóbal Belda-Iniesta, Miguel Gil‐Gil, et al.. (2015). A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma. Clinical & Translational Oncology. 17(9). 743–750. 11 indexed citations

Cloughesy, Timothy F., Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.. (2015). Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data.. Journal of Clinical Oncology. 33(15_suppl). 2015–2015. 26 indexed citations

Hirsch, Fred R., Ramaswamy Govindan, Zanete Zvirbule, et al.. (2014). Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC). International Journal of Radiation Oncology*Biology*Physics. 90(5). S37–S37. 2 indexed citations

Cruz, Jorge Oliver‐De La, Josefa Carrión-Navarro, Noemí Garcia‐Romero, et al.. (2014). SOX2+ Cell Population from Normal Human Brain White Matter Is Able to Generate Mature Oligodendrocytes. PLoS ONE. 9(6). e99253–e99253. 12 indexed citations

Pernía, Olga, Cristóbal Belda-Iniesta, Verónica Pulido, et al.. (2014). Methylation status ofIGFBP-3as a useful clinical tool for deciding on a concomitant radiotherapy. Epigenetics. 9(11). 1446–1453. 11 indexed citations

10.

Conde, Esther, Elisa Izquierdo, Luis Paz‐Ares, et al.. (2013). Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers. Clinical & Translational Oncology. 15(7). 503–508. 24 indexed citations

11.

Castro, Javier de & Cristóbal Belda-Iniesta. (2013). KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.. PubMed. 2(2). 142–51. 16 indexed citations

12.

Casado, E., Víctor Moreno, José Javier Sánchez, et al.. (2011). A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer. Clinical Cancer Research. 17(12). 4145–4154. 25 indexed citations

13.

Batlle, Jaime Feliú, Elena Cuadrado‐Payán, Trinidad Caldés, et al.. (2011). Irinotecan-Cetuximab-Bevacizumab as a Salvage Treatment in Heavily Pretreated Metastatic Colorectal Cancer Patients: A Retrospective Observational Study. Chemotherapy. 57(2). 138–144. 6 indexed citations

14.

Belda-Iniesta, Cristóbal, Javier de Castro, & Rosario Perona. (2010). Translational Proteomics: What Can You Do for True Patients?. Journal of Proteome Research. 10(1). 101–104. 1 indexed citations

15.

Moncho-Amor, Verónica, Inmaculada Ibañez de Cáceres, Eva Bandrés, et al.. (2010). DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer. Oncogene. 30(6). 668–678. 88 indexed citations

16.

Hernando, Eva, Jacinto Sarmentero, Theresa M. Koppie, et al.. (2009). A critical role for choline kinase-α in the aggressiveness of bladder carcinomas. Oncogene. 28(26). 2425–2435. 51 indexed citations

17.

Sereno, María, Antonella Brunello, Alberto Chiappori, et al.. (2008). Cardiac toxicity: old and new issues in anti-cancer drugs. Clinical & Translational Oncology. 10(1). 35–46. 49 indexed citations

18.

Sereno, María, Miguel Ángel García‐Cabezas, Javier de Castro, et al.. (2007). Immunohistochemical expression of p53, Bcl-2, COX-2, C-erb-B2, EPO-R, beta-catenin, and E-cadherin in non tumoral gastric mucous membrane.. PubMed. 50(4). 285–92. 5 indexed citations

19.

Castro, Javier de, et al.. (2007). Carcinoma de pulmón. Dialnet (Universidad de la Rioja). 111–128. 1 indexed citations

20.

Feliú, Jaime, Guillermo Martı́n, Javier de Castro, et al.. (2006). Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 58(4). 527–531. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact